Skip to content
BioalmanacPeptide reference
Account
Menu

Comparison

CJC-1295 vs ipamorelin

The most compared pair in this category, and the comparison is slightly wrong-headed: they act on different receptors and are usually run together rather than chosen between.

This is the most searched comparison in the growth hormone category, and the framing deserves challenging before the table. These two are not really alternatives. They act on different inputs to the same output. That is exactly why the most common protocol in this space uses both.

CJC-1295 is a GHRH analogue: it amplifies the pituitary's primary release signal. Ipamorelin acts on the ghrelin receptor, a separate input that both stimulates release and briefly suppresses the hormone that holds it back. Push two different levers and the resulting pulse is larger than either alone.

Where a genuine choice exists it is usually between short-acting and long-acting CJC-1295, not between CJC-1295 and ipamorelin. That distinction is covered on the CJC-1295 page and is the one worth getting right before buying anything.

CJC-1295 vs ipamorelin compared row by row
AttributeCJC-1295Ipamorelin
ReceptorGHRH receptor. Amplifies the release signalGhrelin receptor. A separate release input
Evidence levelEarly human pharmacology, no outcome trialsEarly human pharmacology, no outcome trials
Effect on GHRaises the size of the pulseTriggers a pulse and briefly suppresses somatostatin
Half-lifeAbout 30 minutes without DAC; about 6–8 days with DACAbout 2 hours
Typical dose scale100–300 mcg without DAC; 1–2 mg weekly with DAC200–300 mcg
Most reported effectFlushing shortly after injectionIncreased hunger. It acts on the hunger receptor
Naming confusionSevere. DAC and non-DAC sold under one name, half-lives differing over a hundredfoldLow. Sold under one name at one scale
Prohibited in sportYes, WADA S2, at all timesYes, WADA S2, at all times

Things worth knowing

  • They are complementary rather than competing. The most common community protocol uses both, on the reasoning that two different inputs produce a larger pulse than one.
  • The real decision with CJC-1295 is DAC versus non-DAC. The sustained form abolishes the pulsatile pattern that the whole class is otherwise argued to preserve. That is close to the opposite of what most people buying it want.
  • Neither has outcome evidence. Both raise growth hormone measurably; neither has been shown in a controlled trial to change body composition, recovery or anything else in healthy adults.
  • Hunger is not a side effect of ipamorelin so much as a consequence of its mechanism. If you are eating at a deficit, that matters.
  • Both raise IGF-1, which is the reason the cancer-history caution on each page is not a formality.

Full profile

CJC-1295

A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.

Full profile

Ipamorelin

A selective growth hormone secretagogue that prompts a short pulse of GH release. Widely used, and supported almost entirely by early pharmacology rather than outcome trials.

Related

Or run bothCJC-1295 and IpamorelinThe standard growth hormone pairing. Two compounds on two different receptors, which is the one combination in this category with a real mechanistic argument.Another comparisonIpamorelin vs GHRP-2Two ghrelin-receptor secretagogues doing the same job. Selectivity is what separates them: one raises growth hormone and little else, the other raises several things at once.Another comparisonSermorelin vs CJC-1295Two GHRH analogues on the same receptor. How long each survives in the body is the difference, and it changes both the schedule and the shape of what comes out.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.